Tag Archives: institute

Prostate cancer prevention trial identifies men mostly likely to undergo challenging study procedure

The Prostate Cancer Prevention Trial was a randomized, double-blind, placebo-controlled trial which tested the efficacy of finasteride, a drug used for prostate cancer prevention. This study was conducted by SWOG — a cancer research cooperative group that designs and conducts multidisciplinary clinical trials…

Long-sought drug candidate can halt tumor growth, scientists demonstrate

Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be “undruggable.” The researchers found that a credit card-like molecule they developed somehow moves in and disrupts the critical interactions between MYC and its binding partner. The research, published the week of August 11 in the journal Proceedings of the National Academy of Sciences, also shows the drug candidate can stop tumor growth in animal models. …

Gene likely to promote childhood cancers pinpointed by researchers

“We and others have found that Lin28b — a gene that is normally turned on in fetal but not adult tissues — is expressed in several childhood cancers, including neuroblastoma, Wilms’ tumor and hepatoblastoma, a type of cancer that accounts for nearly 80 percent of all liver tumors in children,” said Dr. Hao Zhu, a principal investigator at CRI, and Assistant Professor of Pediatrics and Internal Medicine at UT Southwestern Medical Center. “In our study, we found that overproduction of Lin28b specifically causes hepatoblastoma, while blocking Lin28b impairs the cancer’s growth…

Mystery of brain cell growth unraveled by scientists

How a single protein can exert both a push and a pull force to nudge a neuron in the desired direction is a longstanding mystery that has now been solved by scientists from Dana-Farber Cancer Institute and collaborators in Europe and China. Jia-huai Wang, PhD, who led the work at Dana-Farber and Peking University in Beijing, is a corresponding author of a report published in the August 7 online edition of Neuron that explains how one guidance protein, netrin-1, can either attract or repel a brain cell to steer it along its course. Wang and co-authors at the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, used X-ray crystallography to reveal the three-dimensional atomic structure of netrin-1 as it bound to a docking molecule, called DCC, on the axon of a neuron…

Powerful new system for classifying tumors revealed

“It’s only ten percent that were classified differently, but it matters a lot if you’re one of those patients,” said senior author Josh Stuart, a professor of biomolecular engineering at UC Santa Cruz. Stuart helped organize the study as part of the Pan-Cancer Initiative of the Cancer Genome Atlas (TCGA) project…

Genetic testing of tumor is recommended for colorectal cancer patients

Universal Tumor Testing Universal genetic testing of the tumors for evidence of mismatch repair (MMR) deficiency of newly diagnosed colorectal cancer patients is recommended for several reasons: 1. Use of clinical criteria and prediction models to identify patients with Lynch syndrome have less than optimal sensitivity and specificity. 2. It has been shown to be cost effective for the diagnosis of Lynch syndrome. …

Trapped: Cell-invading piece of virus captured in lab by scientists

This achievement sets the stage to use x-ray crystallography to develop complete images of HIV that include integrase, which in turn will help scientists develop new treatments for the illness. Duane Grandgenett, Ph.D., professor at SLU’s Institute of Molecular Virology and senior author of the study, discovered integrase in 1978, little knowing the piece of virus would provide the basis for an entire class of drugs that now treats HIV…

Triple therapy revs up immune system against common brain tumor

Mice with implanted, mouse-derived glioblastoma cells lived an average of 67 days after the triple therapy, compared with mice that lasted 24 days when they received only the two immunotherapies. Half of the mice who received the triple therapy lived 100 days or more and were protected against further tumors when new cancer cells were re-injected under the animals’ skins. The combination treatment described in the July 11 issue of PLOS One consists of highly focused radiation therapy targeted specifically to the tumor and strategies that lift the brakes and activate the body’s immune system, allowing anti-cancer drugs to attack the tumor…